Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

261. Systematic review on heparin-induced thrombocytopenia in children: a call to action. (Abstract)

Systematic review on heparin-induced thrombocytopenia in children: a call to action. Heparin-induced thrombocytopenia (HIT) has increasingly been reported in children as an indication for use of new alternative anticoagulant drugs (NAADs).To systematically review the literature regarding: (i) the incidence and prevalence of seroconversion and HIT and (ii) the clinical/laboratory findings and management of HIT in children.MEDLINE and EMBASE databases were searched for studies that reported

2013 Journal of Thrombosis and Haemostasis

262. Methods for administering subcutaneous heparin during pregnancy. (Abstract)

Methods for administering subcutaneous heparin during pregnancy. Pregnant women with a history of venous thromboembolism (VTE), antithrombin deficiency, or other risk factors for VTE, need heparin (unfractionated heparin (UFH) or low-molecular weight heparin (LMWH)) prophylaxis, mainly through administering subcutaneously. Several methods of administering heparin (UFH or LMWH) subcutaneously have been introduced to prevent adverse pregnant outcomes. The effectiveness and safety of different (...) methods administering subcutaneous heparin (UFH or LMWH) during pregnancy have not been systematically evaluated.To compare the effectiveness and safety of different methods of administering subcutaneous heparin (UFH or LMWH) to pregnant women.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 January 2013) and reference lists of retrieved studies.All randomised controlled trials (individual and cluster) comparing the effectiveness and safety of different methods

2013 Cochrane

263. Suggestion of a meta-analysis: unfractionated heparin vs low-molecular-weight heparin in patients with compromised left ventricular function. (Abstract)

Suggestion of a meta-analysis: unfractionated heparin vs low-molecular-weight heparin in patients with compromised left ventricular function. 23391638 2013 05 29 2013 03 25 1532-8171 31 4 2013 Apr The American journal of emergency medicine Am J Emerg Med Suggestion of a meta-analysis: unfractionated heparin vs low-molecular-weight heparin in patients with compromised left ventricular function. 750-1 10.1016/j.ajem.2012.12.036 S0735-6757(13)00013-2 Koracevic Goran P GP eng Letter Research (...) Support, Non-U.S. Gov't 2013 02 05 United States Am J Emerg Med 8309942 0735-6757 0 Anticoagulants 0 Heparin, Low-Molecular-Weight 9005-49-6 Heparin IM Anticoagulants administration & dosage Fluid Therapy adverse effects Heart Failure etiology Heparin administration & dosage Heparin, Low-Molecular-Weight administration & dosage Humans Ventricular Dysfunction, Left etiology therapy 2012 12 27 2012 12 29 2013 2 9 6 0 2013 2 9 6 0 2013 5 31 6 0 ppublish 23391638 S0735-6757(13)00013-2 10.1016/j.ajem

2013 American Journal of Emergency Medicine

264. Importance of meta-analysis of long-term trials of low-molecular-weight heparin vs vitamin K antagonist in pulmonary embolism. (Abstract)

Importance of meta-analysis of long-term trials of low-molecular-weight heparin vs vitamin K antagonist in pulmonary embolism. 23337178 2013 04 29 2014 11 20 1532-8171 31 3 2013 Mar The American journal of emergency medicine Am J Emerg Med Importance of meta-analysis of long-term trials of low-molecular-weight heparin vs vitamin K antagonist in pulmonary embolism. 627-8 10.1016/j.ajem.2012.12.012 S0735-6757(12)00651-1 Koracevic Goran P GP eng Letter Research Support, Non-U.S. Gov't 2013 01 18 (...) United States Am J Emerg Med 8309942 0735-6757 0 Anticoagulants 0 Heparin, Low-Molecular-Weight 12001-79-5 Vitamin K IM Anticoagulants therapeutic use Heparin, Low-Molecular-Weight therapeutic use Humans Meta-Analysis as Topic Pulmonary Embolism prevention & control Secondary Prevention Vitamin K antagonists & inhibitors 2012 12 04 2012 12 09 2012 12 11 2013 1 23 6 0 2013 1 23 6 0 2013 4 30 6 0 ppublish 23337178 S0735-6757(12)00651-1 10.1016/j.ajem.2012.12.012

2013 American Journal of Emergency Medicine

265. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial (Full text)

Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic (...) unfractionated heparin, to prevent venous thromboembolism, after an acute ischaemic stroke. The authors concluded that the higher cost of enoxaparin was offset by fewer clinical events, compared with unfractionated heparin, particularly for patients with more severe stroke. The study focused on the economic data and was satisfactorily carried out. The authors’ conclusions appear to be robust. Type of economic evaluation Cost-effectiveness analysis Study objective This study examined the clinical and economic

2013 NHS Economic Evaluation Database. PubMed abstract

266. Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. (Full text)

Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Proliferative vitreoretinopathy (PVR) is a significant cause of failure in retinal reattachment surgery. Various pharmacological agents have shown potential benefit in reducing postoperative PVR risk.This review aimed to compare the use of intravitreal low molecular weight heparin (LMWH) alone or with 5-Fluorouracil (5-FU) versus placebo

2013 Cochrane PubMed abstract

267. Thromboelastography-guided heparin use for the prevention of venous thromboembolism

Thromboelastography-guided heparin use for the prevention of venous thromboembolism Thromboelastography-guided heparin use for the prevention of venous thromboembolism Thromboelastography-guided heparin use for the prevention of venous thromboembolism Mitchell MD, Fishman N, Umscheid CA Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Fishman N (...) , Umscheid CA. Thromboelastography-guided heparin use for the prevention of venous thromboembolism. Philadelphia: Center for Evidence-based Practice (CEP). 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Heparin; Humans; Venous Thromboembolism Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535

2013 Health Technology Assessment (HTA) Database.

268. Low Molecular Weight Heparin Volume for Single Site Injection: Evidence-Based Guidelines and Safety

Low Molecular Weight Heparin Volume for Single Site Injection: Evidence-Based Guidelines and Safety Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid (...) of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Low Molecular Weight Heparin

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

269. Relative efficacy of bivalirudin versus heparin monotherapy in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: a network meta-analysis. (Full text)

Relative efficacy of bivalirudin versus heparin monotherapy in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: a network meta-analysis. In the absence of head-to-head clinical data, the objective of this study was to indirectly compare the efficacy and safety of a bivalirudin-based anticoagulation strategy with that of heparin monotherapy in patients with ST-elevation myocardial infarction (STEMI) intended for primary (...) percutaneous coronary intervention. A systematic literature review was performed to identify randomized controlled trials to build a network of bivalirudin and heparin monotherapy strategies in STEMI patients using heparin, with glycoprotein IIb/IIIa inhibitor as a common reference strategy. At 30 days, the bivalirudin-based strategy was expected to result in lower mortality rates than heparin monotherapy (odds ratio [OR], 0.55; credible limit [CrL], 0.32-0.95). This relationship was sustained at 1 year

2013 Journal of blood medicine PubMed abstract

270. Citrate versus unfractionated heparin for anticoagulation in continuous renal replacement therapy. (Abstract)

Citrate versus unfractionated heparin for anticoagulation in continuous renal replacement therapy. Unfractionated heparin is the most commonly used anticoagulant in continuous renal replacement therapy (CRRT), but it can increase the risk of bleeding. Citrate is a promising substitute. Our study was to assess the efficacy and safety of citrate versus unfractionated heparin in CRRT.We searched the MEDLINE, the EMBASE, the Cochrane Central Register of Controlled Trials, and the China National (...) Knowledge Infrastructure Database until up to November 2011 for randomized controlled trials comparing citrate with unfractionated heparin in adult patients with acute kidney injury prescribed CRRT. The primary outcome was mortality and the secondary outcomes included circuit survival, control of uremia, risk of bleeding, transfusion rates, acid-base statuses, and disturbance of sodium and calcium homeostasis.Four trials met the inclusion criteria. Meta-analysis found no significant difference between

2013 Chinese medical journal

271. Heparin for venous thromboembolism prophylaxis in patients with acute spinal cord injury: a systematic review and meta-analysis. (Full text)

Heparin for venous thromboembolism prophylaxis in patients with acute spinal cord injury: a systematic review and meta-analysis. The objective of this study is to systematically review and estimate the effect of heparin for thromboprophylaxis in patients with acute spinal cord injury (SCI).We searched the PubMed database up to February 2013. Only randomized control trials (RCTs), quasi-RCTs, cohorts, case-control and cross-sectional studies were included. The incidence of venous thromboembolism (...) (VTE) and major bleeding complication were recorded as the endpoints. The summary relative risks (RR) were calculated by meta-analysis.A total of 18 studies with 2578 patients were included. Four studies evaluated the effects of low-dose unfractionated heparin (LDUH) compared placebo or untreated. No significant differences were observed, with the summary RR 0.661 (95% confidence interval (CI) 0.365-1.199; Z=1.36, P=0.173) for VTE. Only one RCT compared fixed-dose LDUH with adjusted-dose LDUH

2013 Spinal cord PubMed abstract

272. Use of oral direct factor Xa inhibiting anticoagulants in elective hip and knee arthroplasty: a meta-analysis of efficacy and safety profiles compared with those of low-molecular-weight heparins. (Abstract)

Use of oral direct factor Xa inhibiting anticoagulants in elective hip and knee arthroplasty: a meta-analysis of efficacy and safety profiles compared with those of low-molecular-weight heparins. Assessing the efficacy and safety profiles of new oral direct Factor Xa (FXa) inhibiting anticoagulants compared with low-molecular-weight heparins (LMWHs) in elective total hip and knee arthroplasty (THA and TKA). The literature review only searched for randomised-controlled trials (RCTs) published

2013 Current vascular pharmacology

273. The treatment of venous thromboembolism with low-molecular-weight heparins: a meta-analysis

The treatment of venous thromboembolism with low-molecular-weight heparins: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

274. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials (Abstract)

Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials Anticoagulation of the extracorporeal circuit is required in continuous renal replacement therapy (CRRT). Heparin is the classic choice for anticoagulation, although it may increase the risk of bleeding. Regional citrate anticoagulation reduces the risk of bleeding, but may cause hypocalcemia and metabolic disturbances.Systematic review and meta-analysis (...) of randomized controlled trials (RCTs).Patients admitted to the intensive care unit with acute kidney injury that required CRRT.RCTs regardless of publication status or language.Regional citrate versus heparin anticoagulation in CRRT.The primary outcomes were circuit survival time, the occurrence of major bleeding defined as a site of gross bleeding with a decrease in blood pressure or requiring transfusion of 2 or more units of red blood cells, metabolic alkalosis, hypocalcemia, and thrombocytopenia

2012 EvidenceUpdates

275. Oral anticoagulation continuation compared with heparin bridging therapy among high risk patients undergoing implantation of cardiac rhythm devices: a meta-analysis. (Full text)

Oral anticoagulation continuation compared with heparin bridging therapy among high risk patients undergoing implantation of cardiac rhythm devices: a meta-analysis. It was the objective of this study to systematically compare the effects of oral anticoagulation (OAC) with heparin bridging therapy among patients at high risk for thromboembolism undergoing implantation of cardiac rhythm devices. A systematic search of PubMed/MEDLINE, Ovid and Elsevier, and the Cochrane Library databases (...) to 0.54, p=0.004), respectively, in the OAC continuation group versus the heparin bridging group. We did not detect any statistically significant differences of thromboembolic events (OR 0.48, 95%CI: 0.07 to 3.54, p=0.48) in the two groups. There was a trend that patients in bridging group had longer hospital stays. In conclusion, OAC continuation had a better risk-beneficial ratio and shorter length of hospital stay, and was more convenient to implement compared with heparin bridging therapy among

2012 Thrombosis and haemostasis PubMed abstract

276. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. (Full text)

Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. The 4Ts is a pretest clinical scoring system for heparin-induced thrombocytopenia (HIT). Although widely used in clinical practice, its predictive value for HIT in diverse settings and patient populations is unknown. We performed a systematic review and meta-analysis to estimate the predictive value of the 4Ts in patients with suspected HIT. We searched PubMed, Cochrane

2012 Blood PubMed abstract

277. Efficacy and safety of unfractionated heparin plus glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines

Efficacy and safety of unfractionated heparin plus glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

278. Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence

Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence CADTH Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions No relevant studies were identified that compared the clinical

2012 Health Technology Assessment (HTA) Database.

279. Meta-Analysis of Safety and Efficacy of Uninterrupted Warfarin Compared to Heparin-Based Bridging Therapy During Implantation of Cardiac Rhythm Devices (Abstract)

Meta-Analysis of Safety and Efficacy of Uninterrupted Warfarin Compared to Heparin-Based Bridging Therapy During Implantation of Cardiac Rhythm Devices Optimal management of perioperative anticoagulation in patients undergoing pacemaker or implantable cardioverter-defibrillator implantation is not yet established. We performed a meta-analysis of the published literature to assess the safety and efficacy of perioperative heparin-based bridging therapy versus uninterrupted warfarin therapy (...) in patients undergoing pacemaker or implantable cardioverter-defibrillator implantation. We performed a systematic review of MEDLINE (1950 to 2012), EMBASE (1988 to 2012), Cochrane Controlled Trials Register (fourth quarter 2011), and reports presented at scientific meetings (1994 to 2011). Randomized controlled trials, case-control, or cohort studies comparing the safety and efficacy of uninterrupted warfarin therapy to heparin-based bridging therapy were eligible. Outcomes reported in eligible studies

2012 EvidenceUpdates

280. Dual Antiplatelet Therapy and Enoxaparin or Unfractionated Heparin for patients with ST-elevation Myocardial Infarction: A Review of the Clinical Evidence

Dual Antiplatelet Therapy and Enoxaparin or Unfractionated Heparin for patients with ST-elevation Myocardial Infarction: A Review of the Clinical Evidence Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could (...) -commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Dual Antiplatelet Therapy and Enoxaparin or Unfractionated Heparin for patients with ST-elevation Myocardial Infarction: A Review of the Clinical Evidence DATE: 29 August 2012

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review